Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease

Katelyn Paz, Ryan Flynn, Jing Du, Stacey Tannheimer, Amy J. Johnson, Shuai Dong, Anne Katrien Stark, Klaus Okkenhaug, Angela Panoskaltsis-Mortari, Peter T. Sage, Arlene H. Sharpe, Leo Luznik, Jerome Ritz, Robert J. Soiffer, Corey S. Cutler, John Koreth, Joseph H. Antin, David B. Miklos, Kelli P. MacDonald, Geoffrey R. HillIvan Maillard, Jonathan S. Serody, William J Murphy, David H. Munn, Colby Feser, Michael Zaiken, Bart Vanhaesebroeck, Laurence A. Turka, John C. Byrd, Bruce R. Blazar

Research output: Contribution to journalArticle

Abstract

Chronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality following allotransplant. Activated donor effector T cells can differentiate into pathogenic T helper (Th)-17 cells and germinal center (GC)–promoting T follicular helper (Tfh) cells, resulting in cGVHD. Phosphoinositide-3-kinase-δ (PI3Kδ), a lipid kinase, is critical for activated T cell survival, proliferation, differentiation, and metabolism. We demonstrate PI3Kδ activity in donor T cells that become Tfh cells is required for cGVHD in a nonsclerodermatous multiorgan system disease model that includes bronchiolitis obliterans (BO), dependent upon GC B cells, Tfhs, and counterbalanced by T follicular regulatory cells, each requiring PI3Kδ signaling for function and survival. Although B cells rely on PI3Kδ pathway signaling and GC formation is disrupted resulting in a substantial decrease in Ig production, PI3Kδ kinase-dead mutant donor bone marrow–derived GC B cells still supported BO cGVHD generation. A PI3Kδ-specific inhibitor, compound GS-649443, that has superior potency to idelalisib while maintaining selectivity, reduced cGVHD in mice with active disease. In a Th1-dependent and Th17-associated scleroderma model, GS-649443 effectively treated mice with active cGVHD. These data provide a foundation for clinical trials of US Food and Drug Administration (FDA)–approved PI3Kδ inhibitors for cGVHD therapy in patients.

Original languageEnglish (US)
JournalAmerican Journal of Transplantation
DOIs
StatePublished - Jan 1 2019

Fingerprint

1-Phosphatidylinositol 4-Kinase
Graft vs Host Disease
Germinal Center
Bronchiolitis Obliterans
B-Lymphocytes
Tissue Donors
Helper-Inducer T-Lymphocytes
T-Lymphocytes
Phosphotransferases
Th17 Cells
Regulatory T-Lymphocytes
United States Food and Drug Administration
Cell Survival
Cell Proliferation
Clinical Trials
Morbidity
Lipids
Bone and Bones
Survival
Mortality

Keywords

  • basic (laboratory) research/science
  • graft-versus-host disease (GVHD)
  • immunobiology
  • immunosuppressant - other

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease. / Paz, Katelyn; Flynn, Ryan; Du, Jing; Tannheimer, Stacey; Johnson, Amy J.; Dong, Shuai; Stark, Anne Katrien; Okkenhaug, Klaus; Panoskaltsis-Mortari, Angela; Sage, Peter T.; Sharpe, Arlene H.; Luznik, Leo; Ritz, Jerome; Soiffer, Robert J.; Cutler, Corey S.; Koreth, John; Antin, Joseph H.; Miklos, David B.; MacDonald, Kelli P.; Hill, Geoffrey R.; Maillard, Ivan; Serody, Jonathan S.; Murphy, William J; Munn, David H.; Feser, Colby; Zaiken, Michael; Vanhaesebroeck, Bart; Turka, Laurence A.; Byrd, John C.; Blazar, Bruce R.

In: American Journal of Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Paz, K, Flynn, R, Du, J, Tannheimer, S, Johnson, AJ, Dong, S, Stark, AK, Okkenhaug, K, Panoskaltsis-Mortari, A, Sage, PT, Sharpe, AH, Luznik, L, Ritz, J, Soiffer, RJ, Cutler, CS, Koreth, J, Antin, JH, Miklos, DB, MacDonald, KP, Hill, GR, Maillard, I, Serody, JS, Murphy, WJ, Munn, DH, Feser, C, Zaiken, M, Vanhaesebroeck, B, Turka, LA, Byrd, JC & Blazar, BR 2019, 'Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease', American Journal of Transplantation. https://doi.org/10.1111/ajt.15305
Paz, Katelyn ; Flynn, Ryan ; Du, Jing ; Tannheimer, Stacey ; Johnson, Amy J. ; Dong, Shuai ; Stark, Anne Katrien ; Okkenhaug, Klaus ; Panoskaltsis-Mortari, Angela ; Sage, Peter T. ; Sharpe, Arlene H. ; Luznik, Leo ; Ritz, Jerome ; Soiffer, Robert J. ; Cutler, Corey S. ; Koreth, John ; Antin, Joseph H. ; Miklos, David B. ; MacDonald, Kelli P. ; Hill, Geoffrey R. ; Maillard, Ivan ; Serody, Jonathan S. ; Murphy, William J ; Munn, David H. ; Feser, Colby ; Zaiken, Michael ; Vanhaesebroeck, Bart ; Turka, Laurence A. ; Byrd, John C. ; Blazar, Bruce R. / Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease. In: American Journal of Transplantation. 2019.
@article{9cbceef9153a48e49480a078e0f2533f,
title = "Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease",
abstract = "Chronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality following allotransplant. Activated donor effector T cells can differentiate into pathogenic T helper (Th)-17 cells and germinal center (GC)–promoting T follicular helper (Tfh) cells, resulting in cGVHD. Phosphoinositide-3-kinase-δ (PI3Kδ), a lipid kinase, is critical for activated T cell survival, proliferation, differentiation, and metabolism. We demonstrate PI3Kδ activity in donor T cells that become Tfh cells is required for cGVHD in a nonsclerodermatous multiorgan system disease model that includes bronchiolitis obliterans (BO), dependent upon GC B cells, Tfhs, and counterbalanced by T follicular regulatory cells, each requiring PI3Kδ signaling for function and survival. Although B cells rely on PI3Kδ pathway signaling and GC formation is disrupted resulting in a substantial decrease in Ig production, PI3Kδ kinase-dead mutant donor bone marrow–derived GC B cells still supported BO cGVHD generation. A PI3Kδ-specific inhibitor, compound GS-649443, that has superior potency to idelalisib while maintaining selectivity, reduced cGVHD in mice with active disease. In a Th1-dependent and Th17-associated scleroderma model, GS-649443 effectively treated mice with active cGVHD. These data provide a foundation for clinical trials of US Food and Drug Administration (FDA)–approved PI3Kδ inhibitors for cGVHD therapy in patients.",
keywords = "basic (laboratory) research/science, graft-versus-host disease (GVHD), immunobiology, immunosuppressant - other",
author = "Katelyn Paz and Ryan Flynn and Jing Du and Stacey Tannheimer and Johnson, {Amy J.} and Shuai Dong and Stark, {Anne Katrien} and Klaus Okkenhaug and Angela Panoskaltsis-Mortari and Sage, {Peter T.} and Sharpe, {Arlene H.} and Leo Luznik and Jerome Ritz and Soiffer, {Robert J.} and Cutler, {Corey S.} and John Koreth and Antin, {Joseph H.} and Miklos, {David B.} and MacDonald, {Kelli P.} and Hill, {Geoffrey R.} and Ivan Maillard and Serody, {Jonathan S.} and Murphy, {William J} and Munn, {David H.} and Colby Feser and Michael Zaiken and Bart Vanhaesebroeck and Turka, {Laurence A.} and Byrd, {John C.} and Blazar, {Bruce R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/ajt.15305",
language = "English (US)",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease

AU - Paz, Katelyn

AU - Flynn, Ryan

AU - Du, Jing

AU - Tannheimer, Stacey

AU - Johnson, Amy J.

AU - Dong, Shuai

AU - Stark, Anne Katrien

AU - Okkenhaug, Klaus

AU - Panoskaltsis-Mortari, Angela

AU - Sage, Peter T.

AU - Sharpe, Arlene H.

AU - Luznik, Leo

AU - Ritz, Jerome

AU - Soiffer, Robert J.

AU - Cutler, Corey S.

AU - Koreth, John

AU - Antin, Joseph H.

AU - Miklos, David B.

AU - MacDonald, Kelli P.

AU - Hill, Geoffrey R.

AU - Maillard, Ivan

AU - Serody, Jonathan S.

AU - Murphy, William J

AU - Munn, David H.

AU - Feser, Colby

AU - Zaiken, Michael

AU - Vanhaesebroeck, Bart

AU - Turka, Laurence A.

AU - Byrd, John C.

AU - Blazar, Bruce R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality following allotransplant. Activated donor effector T cells can differentiate into pathogenic T helper (Th)-17 cells and germinal center (GC)–promoting T follicular helper (Tfh) cells, resulting in cGVHD. Phosphoinositide-3-kinase-δ (PI3Kδ), a lipid kinase, is critical for activated T cell survival, proliferation, differentiation, and metabolism. We demonstrate PI3Kδ activity in donor T cells that become Tfh cells is required for cGVHD in a nonsclerodermatous multiorgan system disease model that includes bronchiolitis obliterans (BO), dependent upon GC B cells, Tfhs, and counterbalanced by T follicular regulatory cells, each requiring PI3Kδ signaling for function and survival. Although B cells rely on PI3Kδ pathway signaling and GC formation is disrupted resulting in a substantial decrease in Ig production, PI3Kδ kinase-dead mutant donor bone marrow–derived GC B cells still supported BO cGVHD generation. A PI3Kδ-specific inhibitor, compound GS-649443, that has superior potency to idelalisib while maintaining selectivity, reduced cGVHD in mice with active disease. In a Th1-dependent and Th17-associated scleroderma model, GS-649443 effectively treated mice with active cGVHD. These data provide a foundation for clinical trials of US Food and Drug Administration (FDA)–approved PI3Kδ inhibitors for cGVHD therapy in patients.

AB - Chronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality following allotransplant. Activated donor effector T cells can differentiate into pathogenic T helper (Th)-17 cells and germinal center (GC)–promoting T follicular helper (Tfh) cells, resulting in cGVHD. Phosphoinositide-3-kinase-δ (PI3Kδ), a lipid kinase, is critical for activated T cell survival, proliferation, differentiation, and metabolism. We demonstrate PI3Kδ activity in donor T cells that become Tfh cells is required for cGVHD in a nonsclerodermatous multiorgan system disease model that includes bronchiolitis obliterans (BO), dependent upon GC B cells, Tfhs, and counterbalanced by T follicular regulatory cells, each requiring PI3Kδ signaling for function and survival. Although B cells rely on PI3Kδ pathway signaling and GC formation is disrupted resulting in a substantial decrease in Ig production, PI3Kδ kinase-dead mutant donor bone marrow–derived GC B cells still supported BO cGVHD generation. A PI3Kδ-specific inhibitor, compound GS-649443, that has superior potency to idelalisib while maintaining selectivity, reduced cGVHD in mice with active disease. In a Th1-dependent and Th17-associated scleroderma model, GS-649443 effectively treated mice with active cGVHD. These data provide a foundation for clinical trials of US Food and Drug Administration (FDA)–approved PI3Kδ inhibitors for cGVHD therapy in patients.

KW - basic (laboratory) research/science

KW - graft-versus-host disease (GVHD)

KW - immunobiology

KW - immunosuppressant - other

UR - http://www.scopus.com/inward/record.url?scp=85063123273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063123273&partnerID=8YFLogxK

U2 - 10.1111/ajt.15305

DO - 10.1111/ajt.15305

M3 - Article

C2 - 30748099

AN - SCOPUS:85063123273

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -